Seeking Alpha

Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection

TARRYTOWN, N.Y., Oct. 21, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA ® ...
Oklahoma's News

EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm ...

TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA ® (aflibercept) ...
Seeking Alpha

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and ...

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal ...
Nasdaq

EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and ...

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient ...
Nasdaq

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability ...

TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...